Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company’s public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Enfuvirtide–PEG conjugate: A potent HIV fusion inhibitor with improved pharmacokinetic properties

Shuihong Cheng a, b, 1, Yan Wang c, 1, Zhenxing Zhang a, d, Xun Lv a, George F. Gao a, c, Yiming Shao c, Liying Ma c, **, Xuebing Lia a, b, e, *

1. Introduction

Highly active antiretroviral therapy (HAART) that allows for the simultaneous administration of multiple drugs is currently the standard treatment for HIV infection. The drug combinations used in this setting normally consist of several inhibitors that target different enzymes in the viral life-cycle, including reverse transcriptase, protease, and integrase. Although HAART can dramatically decrease the levels of morbidity and mortality associated with HIV infection, the emergence of drug resistance is usually unavoidable because of the high mutation and rapid replication rates of the virus. The sequential administration of different drugs is therefore required for the treatment of HIV infection, as well as the development of new targeted therapies [1]. Enfuvirtide (ENF) is an important choice for the treatment of patients who have not responded well to HAART. In contrast to traditional small-molecule enzyme inhibitors, ENF is a 36-residue peptide that binds to the viral envelope gp41 protein and inhibits the gp41-mediated membrane fusion between the virus and the host-cell, which is an essential step for the delivery of the viral genome into the cell [2]. ENF has been successfully used in clinic practice to control HIV infection and transmission. However, as is the case with many peptide and protein drugs [3], ENF exhibits poor aqueous solubility and can be rapidly removed from systemic circulation through metabolic pathways and immune response systems. To maintain an efficacious concentration, ENF must be administered twice daily at a high dosage (90 mg) by subcutaneous injections. Furthermore, ENF therapy must be implemented consistently over an extended period of time because of the chronic nature of HIV infection [4].
Chemical and chemoenzymatic syntheses can produce structurally welldefined molecules [25,26], but generally require multiple cation procedures that can result in low production yields, thereby limiting their practical application. Based on our previous experience of the glycosylation of ENF [20], and the fact that PEGLylation has advanced many bioactive proteins and peptides into clinical applications [23], we sought to prepare the ENF−PEG (EP) conjugate as a simple alternative. By controlling the modification site of ENF and the molecular weight (MW) of PEG, we successfully synthesized an EP conjugate with a remarkably improved pharmacokinetic profile. This conjugate formed a strong binding interaction with a functional fragment of the gp41 protein and exhibited potent inhibitory activities towards various HIV isolates that are currently in circulation, with in vitro efficacies comparable to that of ENF. It is therefore envisaged that the results presented in this study will provide a basis for the development of further EP conjugates as long-lasting HIV fusion inhibitors for the treatment of HIV infection.

2. Results and discussion

2.1. Synthesis and characterization of EP conjugates

Following our established glycosylation strategy [20], we investigated the site-specific addition of PEG to the terminus of ENF using a thiol-maleimide coupling reaction (Fig. 1). Two ENF derivatives bearing a single cysteine residue at their N- or C-termini (cENF and ENFc) were modified with methoxy-PEG-maleimides which can lead to severe injection-site reactions [5]. ENF treatment is therefore inconvenient to the patient and represents an expensive regimen for the health care provider, and these factors have severely limited its application in the clinic.

A number of different approaches have been developed to address the pharmacokinetic problems associated with ENF and several other peptide analogues, which can inhibit HIV fusion in a similar manner. Peptide engineering strategies, such as the incorporation of salt bridges, can lead to increases in the in vivo stability of a peptide sequence, which can result in extended half-lives [6–10]. The chemical modification of a peptide with a synthetic or natural molecule, such as cholesterol [11] or albumin [12,13], can also lead to a reduction in its immunogenicity and proteolysis [14–20]. Polyethylene glycol (PEG) conjugation is a commonly used method for improving the pharmacokinetics of therapeutic peptides and proteins [21–23], and this method has been applied to a peptide inhibitor of HIV fusion that overlaps ENF by 33 residues [19]. The PEGLated peptide showed a 3.4-fold increase in the half-life against tryptic degradation, although there was a slight decrease in the fusion-inhibitory potency when compared with the unmodified peptide. Despite the positive results reported in this study for the PEGLation of the inhibitor, there have been no reports in the literature to date pertaining to the antiviral activity or the pharmacokinetic properties of a fusion inhibitor conjugated with PEG.

As part of our ongoing research towards the development of persistent inhibitors against HIV fusion, we previously developed a series of glycosylated ENFs with long in vivo half-lives that completely retained their antiviral activities [20]. In a similar manner to PEGLylation, the glycosylation of peptides and proteins leads to an increase in their molecular size and steric bulk, which can have a significant impact on their biophysical and physiological properties. However, current techniques for the construction of glycopeptides and glycoproteins are quite challenging. Recombinant expression systems allow for the rapid and large-scale production of glycopeptides and glycoproteins, but these systems provided only limited control over the glycosylation step [24]. Chemical and chemoenzymatic syntheses can produce structurally well-defined molecules [25,26], but generally require multiple steps and tedious purification procedures that can result in low production yields, thereby limiting their practical application.

Based on our previous experience of the glycosylation of ENF [20], and the fact that PEGLylation has advanced many bioactive proteins and peptides into clinical applications [23], we sought to prepare the ENF−PEG (EP) conjugate as a simple alternative. By controlling the modification site of ENF and the molecular weight (MW) of PEG, we successfully synthesized an EP conjugate with a remarkably improved pharmacokinetic profile. This conjugate formed a strong binding interaction with a functional fragment of the gp41 protein and exhibited potent inhibitory activities towards various HIV isolates that are currently in circulation, with in vitro efficacies comparable to that of ENF. It is therefore envisaged that the results presented in this study will provide a basis for the development of further EP conjugates as long-lasting HIV fusion inhibitors for the treatment of HIV infection.

2.2. Binding of EP conjugates to a functional domain of gp41

To ensure that the modified ENF retained its binding affinity for the HIV gp41 protein, we measured the strength of the binding interaction between the conjugates and a functional fragment of gp41 known as N46, which contains the full binding region for ENF [27–29]. Surface plasmon resonance (SPR) experiments showed that all the conjugates strongly bound to N46 with affinities (Kd) in the range of 307–1410 nM (Fig. 2). Although the affinities of the conjugates were lower than that of ENF (182 nM), we observed a general trend towards increasing affinity as the MW of the PEG portion of the conjugate decreased.
Particularly, the PEG2k-ENF demonstrated an affinity (307 nM) approximating to that of ENF. In contrast, none of the EP conjugates or ENF bound to bovine serum albumin (BSA), confirming that the observed interactions were specific for peptide N46. The SPR experiments measured the binding of ENF or EP conjugates to the chip-immobilized N46, and the assay condition did not exactly match with the membrane environment necessary for the fusion inhibition. However, the potent interaction between EP conjugates and N46 confirmed in this assay suggested that the attached PEG had no significant impact on the intrinsic binding affinity of ENF.

2.3. Secondary structure of EP conjugates and their complex with N46

Peptide conformation can have a remarkable effect on the antiviral activity of fusion inhibitors [27–32]. ENF lacks a defined structure in solution, where it has a low α-helicity. In contrast, N46 adopts a typical α-helical conformation in solution, and its α-helicity is reduced dramatically upon its binding to ENF. The ENF and EP conjugates prepared in this study were analyzed by circular dichroism (CD), and the results revealed that the low α-helical content of ENF was further decreased by the attached PEG in a MW-dependent manner (Fig. 3A). Interestingly, all of the conjugates interacted with N46 to form stable α-helical complexes, which had markedly higher α-helicitics than that of N46 alone or in complex with ENF (Fig. 3B). This result is, however, inconsistent with the affinity of the conjugates for N46 which is obviously lower than that of ENF.

2.4. Antiviral activity of EP conjugates against a laboratory-adapted HIV

Having established that the EP conjugates could bind to the gp41 fragment to form high affinity complexes with high α-helicities, we examined their antiviral activities against a laboratory-adapted HIV-1 strain SF33. The replication of the virus in TZM-bl cells [39] was measured in the presence of ENF or the conjugates using an XTT assay [41]. The two conjugates bearing smaller PEG (2 kDa) showed higher activities than their 5 kDa counterparts. The N-terminally PEGylated peptides showed much greater activity than their C-terminal congeners, with the PEG2k-ENF exhibiting the highest inhibitory activity of all the inhibitors.

Table 1

| Inhibitors       | EC50 (nM) | EC90 (nM) | CC50 (μM) | SI       |
|------------------|-----------|-----------|-----------|----------|
| ENF              | 3 ± 0     | 23 ± 2    | >100      | >33,333  |
| PEG2k-ENF        | 4 ± 0     | 44 ± 9    | >100      | >25,000  |
| PEG5k-ENF        | 8 ± 1     | 84 ± 3    | >100      | >12,500  |
| ENF-PEG2k        | 12 ± 3    | 250 ± 7   | >100      | >33,333  |
| ENF-PEG5k        | 19 ± 2    | 362 ± 2   | >100      | >5263    |

The EC50 and EC90 values were determined using the Reed and Muench method [40] after the incubation of TZM-bl cells with virus in the presence of ENF or an EP conjugate. All of these experiments were performed in triplicate and the results were reported as the mean value ± standard deviation (SD).

The CC50 values were determined with TZM-bl cells.

SI (selectivity index): CC50/EC50.
conjugates. Notably, the EC_{50} value of PEG2k-ENF (4 nM) was comparable to that of ENF (3 nM). The chemical modification at the C-terminus of ENF has an adverse impact on its antiviral activity [11,12,20], because the lipophilic residues (WNWF) in this region are required for the anchoring of the peptide into the membrane interface where the fusion occurs [28,29]. Our data were therefore in agreement with these earlier findings and revealed that the attachment of PEG2k to the N-terminus of ENF did not lead to a significant decrease in its antiviral efficacy.

2.5. Pharmacokinetics of PEG2k-ENF in rats

We next analyzed the pharmacokinetics of PEG2k-ENF in rats following the subcutaneous injection of a single dose of this material (Fig. 4). In contrast to ENF, which was both rapidly adsorbed and rapidly cleared from systemic circulation, the EP conjugate showed a slower but more sustained release profile from the injection site. The calculation of pharmacokinetic parameters using the well-established non-compartmental method [44] revealed that the conjugate had an elimination half-life [45] (T_{1/2}) which was over 10-fold longer than that of ENF. The overall pharmacokinetic profile of PEG2k-ENF was also superior to that of ENF, with marked increases in the area under the plasma concentration time curve (AUC), apparent volume of distribution (V_d), and mean residence time (MRT), as well as a marked decrease in systematic clearance rate (CL). This improvement in pharmacokinetic profile, as generally seen for many other PEGylated protein or peptide therapeutics [21–23], makes the EP conjugate attractive as a long-lasting fusion inhibitor to address the unmet medical needs associated with the treatment of HIV infection.

2.6. Antiviral spectrum of PEG2k-ENF

To further evaluate the therapeutic potential of PEG2k-ENF, we examined its antiviral spectrum using fourteen HIV-1 viruses of different subtypes, including five B′ (also known as Thai B′), five BC, and four AE isolates, all of which represent the predominant strains currently circulating in China [46–49]. The PEG2k-ENF inhibited the replication of these viruses in TZM-bl cells as efficacious as ENF, with activities (EC_{50}) in the low-nanomolar range (Table 2) and selectivity indices (SI) greater than 1000. Taken together with its remarkably improved pharmacokinetic properties, the broad and potent antiviral activities of PEG2k-ENF show that the EP conjugates warrant further preclinical and clinical evaluations.

3. Conclusions

We have demonstrated that the site-specific PEGylation of ENF improved its pharmacokinetic profile without discernible decrease in its antiviral activity. The coupling of cENF to mPEG-MAL through a concise thiol-maleimide reaction allowed for the large-scale synthesis of the EP conjugate, which could be important for clinical applications that require a sufficient supply of material. The EP conjugate exhibited much better aqueous solubility and in vivo half-life than ENF, which could lead to less-frequent dosing regimens and a reduction in adverse injection-site reactions. In addition, the EP conjugate displayed potent inhibitory activity towards the most common primary HIV strains circulating in China, further highlighting its potential as an effective and long-acting inhibitor of HIV fusion. It is noteworthy that a number of other enveloped viruses, including Ebola virus, Middle East respiratory syndrome coronavirus (MERS-CoV), and severe acute respiratory syndrome

![Fig. 4. Pharmacokinetic analysis in Sprague–Dawley rats. ENF and PEG2k-ENF were subcutaneously administered at 1.7 μmol/kg (in physiological saline). Four animals per group were used. (A) Pharmacokinetic curves. The concentrations of ENF and the conjugate in plasma were determined using a known HPLC analysis [42,43]. Error bars indicate the SD. (B) Pharmacokinetic parameters. Values were calculated using the non-compartmental analysis [44] (NCA,WinNonlin, version 6.2, Pharsight, Carlsbad, CA) and expressed as the mean values ± SD. T_{1/2} (elimination half-life or terminal half-life) [45] refers to the time required for the concentration of remaining drug in plasma to be reduced by 50% after the pseudo-equilibrium of drug distribution in the body has been reached.

Table 2

| Viruses | EC_{50} (nM) | SI | ENF | PEG2k-ENF | ENF | PEG2k-ENF |
|---------|-------------|----|-----|-----------|-----|-----------|
| Subtype B′ |             |    |     |           |     |           |
| 20100259 | 38 ± 4      | 44 ± 2 | >2632 | >2273     |
| 20100968 | 54 ± 5      | 64 ± 6 | >1852 | >1563     |
| 20100996 | 51 ± 4      | 68 ± 2 | >1961 | >1471     |
| 20100311 | 14 ± 2      | 20 ± 2 | >7143 | >5000     |
| 20100104 | 44 ± 2      | 47 ± 1 | >2273 | >2128     |
| Subtype BC |             |    |     |           |     |           |
| XJDC6371 | 53 ± 8      | 58 ± 6 | >1887 | >1724     |
| CBJR256  | 40 ± 4      | 46 ± 4 | >2500 | >2174     |
| XJDC6291 | 50 ± 9      | 42 ± 1 | >2000 | >2381     |
| CBJR257  | 85 ± 7      | 91 ± 8 | >1177 | >1099     |
| XJDC6331 | 50 ± 7      | 59 ± 5 | >2000 | >1695     |
| Subtype AE |             |    |     |           |     |           |
| CYM033   | 65 ± 3      | 71 ± 4 | >1539 | >1409     |
| BJMSM376 | 24 ± 1      | 26 ± 3 | >4167 | >3846     |
| BJMSM543 | 56 ± 4      | 60 ± 1 | >1786 | >1667     |
| CYM015   | 5 ± 1       | 6 ± 1 | >20,000 | >1667     |

*EC_{50} was determined using the Reed and Muench method [40] after the incubation of TZM-bl cells with virus in the presence of ENF or PEG2k-ENF. Values are from triplicate assays and shown as the mean ± SD.

SI = CC_{50}/EC_{50}. The CC_{50} values of both peptides were greater than 100 μM, as determined with TZM-bl cells.
coronavirus (SARS-CoV), have similar mechanisms of virus–cell fusion to that observed in HIV infection. With this in mind, it is envisaged that the peptide inhibitors currently under investigation against these viruses [50–53] could also be subjected to the PEGylation approach described in this study.

4. Experimental procedures

4.1. Materials and instrumentation

All peptides used in this study were synthesized using a solid-phase Fmoc method at Beijing Scilight Biotechnology LLC (Beijing, China), purified by HPLC (purity >95%), and characterized by MALDI–TOF MS. The sources of HIV-1SF33 and TZM-bl, as well as the methods used for their preservation and passage have been described previously [20,41]. The clinical isolates of HIV-1 subtypes B’, BC, and AE were obtained from treatment-naive patients and stored at our laboratory in Chinese Center for Disease Control and Prevention [46,47]. These viruses represent the predominant strains circulating in China from 2005 to 2008. Sprague-Dawley rats (male, 7 weeks old, and 150–180 g) were purchased from Beijing HFK Bioscience (Beijing, China) and fed for 2 days before being used for pharmacokinetic analysis. PEG-MAL (2 and 5 kDa) was purchased from Beijing Kaizheng Biotech Development (Beijing, China). All of the other chemicals used in this study were purchased as the analytical grade from various commercial sources. HPLC analyses were performed on an Agilent 1200 system (Agilent, USA) equipped with a UV detector. MALDI-TOF mass spectra were recorded on a Bruker BIFLEX III spectrometer (Bruker Daltonics, Germany). All experiments with the viruses were performed in an approved biosafety level (BSL-3) containment laboratory.

4.2. Synthesis of EP conjugates

An aqueous solution of disodium hydrogen phosphate (5 mM) was added in a dropwise manner to a stirred mixture of cysteine-incorporated ENF (cENF or ENFc, 10 mg, 2 μmol) and mPEG-MAL (2 or 5 kDa, 2 equiv) in a sodium phosphate buffer (5 mL, 5 mM, pH 7.5) to adjust the pH of the mixture to 7.2. The resulting mixture was then stirred for 10 min at rt before being directly purified by preparative HPLC to afford PEG2k-ENF (12 mg, 90%), ENF-PEG2k (11 mg, 85%), PEG5k-ENF (15 mg, 82%), or ENF-PEG5k (15 mg, 82%) as a white powder. The HPLC chromatographic conditions are provided in Fig. 1.

4.3. SPR assay

The binding affinities of EP conjugates to peptide N46 were analyzed by a Biacore biosensor system (Biacore 3000, Biacore Co., Ltd, Sweden), using a previously described procedure [20]. Briefly, N46 was immobilized on a carboxymethyl dextran-coated sensor chip (CM-5, research grade) using a standard primary amine-coupling protocol. Solutions of EP conjugates in PBS containing Tween 20 (0.05% v/v) at different concentrations (0.125–4 μM) were then flowed over the surface of the sensor at a rate of 20 μl/min, and the responses were recorded. ENF was used as a positive control instead of EP conjugate. BSA was used as a negative control instead of peptide N46. The binding kinetic parameters were calculated using the Biacore evaluation software (version 4.1), and the results are shown in Table S1.

4.4. CD analysis

The secondary structures of ENF and EP conjugates were analyzed both in the absence and the presence of peptide N46 using a Chirascan spectropolarimeter (Applied Photophysics Ltd, UK). Measurements were conducted using solutions of the peptides in PBS (5 mM, pH 7.2) as described previously [20]. A concentration of 35 μM was used for both ENF/EP conjugates and peptide N46.

4.5. HIV inhibition assay

The antiviral activities of ENF and EP conjugates against both the laboratory-adapted HIV-1SF33 and the clinical HIV-1 isolates (subtypes B’, BC, and AE) were determined in TZM-bl cell cultures, as described previously [20,46]. Briefly, TZM-bl cells grown on a tissue culture plate (105/well) were inoculated with 200 TCID50 of the virus in the presence and absence of ENF or an EP conjugate (100 μL, in DMEM, at different concentrations from 1.2 to 1000 nM). After incubation at 37 °C for 48 h, the cells (100 μL) were harvested and lysed using a lysing reagent (100 μL, Promega). The activity of the luciferase expressed by TZM-bl cells was then measured, and the EC50 and EC90 values were calculated using the Reed and Muench method [40] based on the percentage inhibition of the luciferase activity.

4.6. Cytotoxicity test

The cytotoxicity of EP conjugates was measured in TZM-bl cells following a standard XTT assay protocol [20,41,54].

4.7. Pharmacokinetic analysis

Sprague-Dawley rats (n = 4) were given a single subcutaneous injection of ENF or PEG2k-ENF at a dosage of 1.7 μmol/kg (in physiological saline). The collection and processing of blood sample, the determination of peptide concentration, and the evaluation of pharmacokinetics were performed as described previously [20]. A known HPLC method [42,43] was used to identify the plasma concentrations of ENF and PEG2k-ENF. The HPLC conditions were as follows: Waters RP-HPLC column (XSELECT CSH 15 μm, 4.6 × 150 mm, Waters), 30 → 52% CH3CN/H2O (containing 0.1 v/v% TFA) gradient at 0.6–1.2 mL/min, UV detection at 220 nm.

Acknowledgments

This work was financially supported by the Ministry of Science and Technology of China through the 973 Program (2012CB518803), the National Natural Science Foundation of China (Grant Nos. 81001389, 31470801, 21202195, and 81273381), and the Open Project Program of National Engineering Research Center for Carbohydrate Synthesis, Jiangxi Normal University.

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.ejmech.2016.05.027.

References

[1] E. De Clercq, The design of drugs for HIV and HCV, Nat. Rev. Drug Discov. 6 (2007) 1001–1018.
[2] J.S. Cervia, M.A. Smith, Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor, Clin. Infect. Dis. 37 (2003) 1102–1106.
[3] M. Werle, A. Bernkop-Schnürch, Strategies to improve plasma half life time of peptide and protein drugs, Amino Acids 30 (2006) 351–367.
[4] S.G. Deeks, S.R. Lewin, D.V. Havlir, The end of AIDS: HIV infection as a chronic disease, Lancet 382 (2013) 1525–1533.
[5] R.A. Mirza, G.W. Turansky, Enfuvirtide and cutaneous injection-site reactions, J. Drugs Dermatol. 11 (2012) e35–e38.
[6] J.J. Dwyer, K.L. Wilson, D.K. Davison, S.A. Free, J.E. Seedorff, S.A. Wring, N.A. Tvermoes, T.J. Matthews, M.L. Greenberg, M.K. Delmedico, Design of helical, oligomeric HIV-1 fusion inhibitor peptides with potent activity against
enfuvirtide-resistant virus, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 12772–12777.

[7] Y. He, Y. Xiao, H. Song, Q. Liang, D. Ju, X. Chen, H. Lu, W. Jing, J. Sang, J. Zhang. Design and evaluation of sfvifuridome, a novel HIV-1 fusion inhibitor. J. Biol. Chem. 283 (2008) 11126–11134.

[8] Y. He, J. Cheng, H. Lu, L. Ju, J. Hu, Z. Qi, Z. Li, S. Jiang, G. Dai. Potent HIV fusion inhibition against enfuvirtide-resistant HIV-1 strains, Proc. Natl. Acad. Sci. U. S. A. 105 (2008) 16332–16337.

[9] S.K. Sia, P.A. Carr, A.G. Cochran, V.N. Malashkevich, P.S. Kim. Short constrained peptides that inhibit HIV entry, Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 16346–16350.

[10] B.D. Welch, A.P. VanDemark, A. Heroux, C.P. Hill, M.S. Kay, Potent D-peptide inhibitors of HIV-1 entry, Proc. Natl. Acad. Sci. U. S. A. 104 (2007) 16828–16833.

[11] P. Balasubramanian, L. Bianchi, N.A. Ladwa, Y.J. Wang, R. Hrin, M. Veneziano, F. Bonelli, T.J. Ketas, J.P. Moore, M.D. Miller, A. Pessis. Addition of a cholesterol group to an HIV-1 fusion protein inhibitor dramatically increases its antiviral potency. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 5801–5806.

[12] C.A. Stoddart, G. Nault, S.A. Galkina, K. Thibaudeau, P. Bakis, N. Bousquet-Gagnon, M. Robitaille, M. Bellono, V. Paradis, P. Liscourt, A. Lobach, M.E. Rivard, R.G. Ptak, M.K. Mankowski, D. Brindis, O. Qurashi. Albumin-conjugated C34 HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCD-huThy/lym mice. J. Biol. Chem. 283 (2008) 34045–34052.

[13] D. Xie, C. Yao, L. Wang, W. Min, J. Xu, J. Xiao, M. Huang, B. Chen, B. Liu, X. Li, H. Jiang. An albumin-conjugated peptide inhibitor of HIV-1 with anti-HIV activity and a long half-life. Antimicrob. Agents Chemother. 54 (2010) 191–196.

[14] C. Wang, L. Lu, H. Xi, N. Li, Q. Wang, X. Jiang, X. Xu, F. Yu, T. Zhang, J. Li, Z. Zhang, B. Zheng, C. Liang, L. Cai, S. Jiang, K. Liu. Conjugation of a non-specific antigen loop with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics. J. Med. Chem. 57 (2014) 7342–7354.

[15] T. Huet, O. Kerbarh, D. Schols, P. Clayette, C. Gauchet, G. Dubreucq, L. Vincent. Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 54 (2010) 134–142.

[16] W. Huang, S. Groothuys, A. Heredia, B.H. Kuipers, F.P. Rutjes, F.L. van Delft, L.X. Wang. Enzymatic glycosylation of triazole-linked GlcNac/ Glc-peptides: synthesis, stability and anti-HIV activity of triazole-linked HIV-1 gp41 glycopeptide C34 analogues. ChemBioChem 10 (2009) 1239–1244.

[17] S. Ding, T.M. Barber, C. Gu, V. Oren, A. Salvador, J. Lemoine, B. Lucidi, J. Balzarini, M. Petittou, Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 54 (2010) 134–142.

[18] C.A. Stoddart, G. Nault, S.A. Galkina, K. Thibaudeau, P. Bakis, N. Bousquet-Gagnon, M. Robitaille, M. Bellono, V. Paradis, P. Liscourt, A. Lobach, M.E. Rivard, R.G. Ptak, M.K. Mankowski, D. Brindis, O. Qurashi. Albumin-conjugated C34 HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCD-huThy/lym mice. J. Biol. Chem. 283 (2008) 34045–34052.

[19] D. Xie, C. Yao, L. Wang, W. Min, J. Xu, J. Xiao, M. Huang, B. Chen, B. Liu, X. Li, H. Jiang. An albumin-conjugated peptide inhibitor of HIV-1 with anti-HIV activity and a long half-life. Antimicrob. Agents Chemother. 54 (2010) 191–196.

[20] C. Wang, L. Lu, H. Xi, N. Li, Q. Wang, X. Jiang, X. Xu, F. Yu, T. Zhang, J. Li, Z. Zhang, B. Zheng, C. Liang, L. Cai, S. Jiang, K. Liu. Conjugation of a non-specific antigen loop with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics. J. Med. Chem. 57 (2014) 7342–7354.

[21] T. Huet, O. Kerbarh, D. Schols, P. Clayette, C. Gauchet, G. Dubreucq, L. Vincent. Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 54 (2010) 134–142.

[22] W. Huang, S. Groothuys, A. Heredia, B.H. Kuipers, F.P. Rutjes, F.L. van Delft, L.X. Wang. Enzymatic glycosylation of triazole-linked GlcNac/ Glc-peptides: synthesis, stability and anti-HIV activity of triazole-linked HIV-1 gp41 glycopeptide C34 analogues. ChemBioChem 10 (2009) 1239–1244.

[23] S. Ding, T.M. Barber, C. Gu, V. Oren, A. Salvador, J. Lemoine, B. Lucidi, J. Balzarini, M. Petittou, Long-lasting enfuvirtide carrier pentasaccharide conjugates with potent anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 54 (2010) 134–142.

[24] C.A. Stoddart, G. Nault, S.A. Galkina, K. Thibaudeau, P. Bakis, N. Bousquet-Gagnon, M. Robitaille, M. Bellono, V. Paradis, P. Liscourt, A. Lobach, M.E. Rivard, R.G. Ptak, M.K. Mankowski, D. Brindis, O. Qurashi. Albumin-conjugated C34 HIV-1 fusion inhibitor: equipotent to C34 and T-20 in vitro with sustained activity in SCD-huThy/lym mice. J. Biol. Chem. 283 (2008) 34045–34052.

[25] D. Xie, C. Yao, L. Wang, W. Min, J. Xu, J. Xiao, M. Huang, B. Chen, B. Liu, X. Li, H. Jiang. An albumin-conjugated peptide inhibitor of HIV-1 with anti-HIV activity and a long half-life. Antimicrob. Agents Chemother. 54 (2010) 191–196.

[26] C. Wang, L. Lu, H. Xi, N. Li, Q. Wang, X. Jiang, X. Xu, F. Yu, T. Zhang, J. Li, Z. Zhang, B. Zheng, C. Liang, L. Cai, S. Jiang, K. Liu. Conjugation of a non-specific antigen loop with a specific HIV fusion inhibitor: a promising strategy for discovering new antiviral therapeutics. J. Med. Chem. 57 (2014) 7342–7354.